Industry
Biotechnology
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Loading...
Open
34.73
Mkt cap
2.4B
Volume
791K
High
34.73
P/E Ratio
-10.01
52-wk high
37.00
Low
33.36
Div yield
N/A
52-wk low
13.39
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 6:43 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 10:41 am
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 7:44 am
Portfolio Pulse from Vandana Singh
June 05, 2024 | 7:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 1:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 4:35 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 10:44 am
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 10:21 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.